Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Jaeger

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
American Journal of Human Genetics|September 24, 2004
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorderColin A Hodgkinson, David Goldman, Judith Jaeger, et al.
American Journal of Medical Genetics|July 13, 2002
No evidence for phenotypic variation between probands in case-control versus family-based association studies of schizophreniaAnil K Malhotra, John A Bates, Judith Jaeger, et al.
Alzheimer'S Research & Therapy|March 19, 2013
Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairmentCurtis Tatsuoka, Huiyun Tseng, Judith Jaeger, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 9, 2023
An adapted clinical global Impression of improvement for use in Angelman syndrome: Validation analyses utilizing data from the NEPTUNE studyPamela Ventola, Judith Jaeger, Christopher J Keary, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 28, 2013
Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trialsJonathan Rabinowitz, Nomi Werbeloff, Ivo Caers, et al.
Chest|November 11, 2024
Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP): A Randomized Placebo-Controlled Double-Blind Repeated-Measures Crossover Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive ImpairmentHans P A Van Dongen, Eileen B Leary, Christopher Drake, et al.
International Psychogeriatrics|November 22, 2018
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria - CORRIGENDUMZahinoor Ismail, Jennifer Gatchel, Daniel R Bateman, et al.
Psychopharmacology|May 4, 2013
A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorderAurelija Jucaite, John Öhd, Alexandra S Potter, et al.
International Psychogeriatrics|September 14, 2017
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoriaZahinoor Ismail, Jennifer Gatchel, Daniel R Bateman, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2019
Practical algorithms for amyloid β probability in subjective or mild cognitive impairmentNancy Maserejian, Shijia Bian, Wenting Wang, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
American Journal of Human Genetics|September 24, 2004
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorderColin A Hodgkinson, David Goldman, Judith Jaeger, et al.
American Journal of Medical Genetics|July 13, 2002
No evidence for phenotypic variation between probands in case-control versus family-based association studies of schizophreniaAnil K Malhotra, John A Bates, Judith Jaeger, et al.
Alzheimer'S Research & Therapy|March 19, 2013
Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairmentCurtis Tatsuoka, Huiyun Tseng, Judith Jaeger, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 9, 2023
An adapted clinical global Impression of improvement for use in Angelman syndrome: Validation analyses utilizing data from the NEPTUNE studyPamela Ventola, Judith Jaeger, Christopher J Keary, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 28, 2013
Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trialsJonathan Rabinowitz, Nomi Werbeloff, Ivo Caers, et al.
Chest|November 11, 2024
Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP): A Randomized Placebo-Controlled Double-Blind Repeated-Measures Crossover Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive ImpairmentHans P A Van Dongen, Eileen B Leary, Christopher Drake, et al.
International Psychogeriatrics|November 22, 2018
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria - CORRIGENDUMZahinoor Ismail, Jennifer Gatchel, Daniel R Bateman, et al.
Psychopharmacology|May 4, 2013
A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorderAurelija Jucaite, John Öhd, Alexandra S Potter, et al.
International Psychogeriatrics|September 14, 2017
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoriaZahinoor Ismail, Jennifer Gatchel, Daniel R Bateman, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2019
Practical algorithms for amyloid β probability in subjective or mild cognitive impairmentNancy Maserejian, Shijia Bian, Wenting Wang, et al.
Pageof 7